Search results

Filter (6 in use)

Area of interest

  • Filter by COVID-19 (2)

Type 4 selected

  • Remove filter for NICE advice (2)
  • Remove filter for Indicators
  • Remove filter for NICE Pathways
  • Remove filter for Local practice

Last updated 1 selected

  • Filter by Last 3 months
  • Remove filter for Last 6 months
  • Filter by Last year
  • Filter by Last 3 years

Advice programme 1 selected

  • Filter by Medtech innovation briefings (25)
  • Filter by Evidence summaries (6)
  • Filter by Antimicrobial prescribing (3)
  • Remove filter for COVID-19 rapid summaries (2)

2 results

Sorted by Relevance . | Sort by Date

  • NICE advice Remove NICE advice filter
  • Indicators Remove Indicators filter
  • NICE Pathways Remove NICE Pathways filter
  • Local practice Remove Local practice filter
  • Last 6 months Remove Last 6 months filter
  • COVID-19 rapid summaries Remove COVID-19 rapid summaries filter
  1. COVID-19 rapid evidence summary: Tocilizumab for COVID-19 (ES33)

    ES33 Product overview The content of this evidence summary was up to date in January 2021. See summaries of product characteristics

    Type
    Evidence summary: COVID-19 rapid summary
    Published
    15 January 2021
  2. COVID-19 rapid evidence summary: Sarilumab for COVID-19 (ES34)

    ES34 Product overview The content of this evidence summary was up to date in January 2021. See summaries of product characteristics

    Type
    Evidence summary: COVID-19 rapid summary
    Published
    20 January 2021